EIR Ventures
VC Fund
Stockholm, Sweden
EIR Ventures is a new Life Science Venture Group in the Nordics.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 54%
- Fund size:
- $138M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries EIR Ventures invests in
Stages EIR Ventures invests in
Countries EIR Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $20M–$73M
Investment Focus
Industry
- Biotechnology 9 (69%)
- Health Care 3 (23%)
- Therapeutics 2 (15%)
- Pharmaceutical 2 (15%)
- Health Diagnostics 2 (15%)
Stage
- Series A 4 (31%)
- Funding Round 3 (23%)
- Seed 2 (15%)
- Series B 1 (8%)
- Series D 1 (8%)
Country
- Denmark 4 (31%)
- Sweden 3 (23%)
- United States 1 (8%)
- The Netherlands 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andreas Segerros
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
Lene Gerlach
Partner
|
Partner | Total investments: 6 | Find email | |
Stephan Christgau
Managing Partner
|
Managing Partner | Total investments: 6 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Moleculent
|
Moleculent is on a mission to develop technology-enabled products that leverage new insights into the molecular foundation of human biology. Developing amazing products to advance human health gives you purpose. they believe that our understanding of the molecular basis of human biology, in health and disease will increase radically in the comingten years. This will lead to a vast improvement in therapies, diagnostics, and a new, fundamental understanding | $20M / Series A / Apr 30, 2026 | |
|
Moleculent
|
Moleculent is on a mission to develop technology-enabled products that leverage new insights into the molecular foundation of human biology. Developing amazing products to advance human health gives you purpose. they believe that our understanding of the molecular basis of human biology, in health and disease will increase radically in the comingten years. This will lead to a vast improvement in therapies, diagnostics, and a new, fundamental understanding | $26M / Series A / Jun 11, 2024 | |
ArgusEye
|
ArgusEye is a biotechnology company that provides sensor solutions for real-time detection of biological systems and processes. ArgusEye's patented sensor technology is the result of extensive academic research and is based on nanoplasmonic sensing with fiber optics. By adding customized receptors, ArgusEye can offer flexible and sensitivesensing systems for a variety of targets. | $3M / Venture - Series Unknown / May 13, 2024 | |
Hoba Therapeutics
|
Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain. | $24.8M / Series A / Dec 11, 2023 | |
Henlez
|
Henlez uses precise enzymes to create disruptive topical treatments for recurrent follicular skin problems. The company can be reached via mail, phone, or physical address. | $988.4K / Seed / Oct 24, 2022 | |
Pretzel Therapeutics
|
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinatingfeatures that make it unlike any other organelle in the body. | $72.5M / Series A / Sep 12, 2022 | |
Synklino
|
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation. | $32M / Series A / Jun 08, 2022 | |
Cinclus Pharma
|
Cinclus Pharma AG is a research based biotech company developing small molecules for the treatment of gastric acid related diseases. Their main asset, X842, has been studied in a Phase I clinical trial. Cinclus Pharma is based in Basel, Switzerland. | $24.1M / Venture - Series Unknown / May 20, 2022 | |
Scenic Biotech
|
Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors as a new class of drug targets.The company's immunotherapy technologies tackle diseases on the genetic level and focuses on disease suppressing genes., it uses genomics to develop innovative therapies for patients affected by severediseases. | $31M / Series A / Mar 09, 2022 | |
Strike Pharma AB
|
Headquartered in Uppsala, Sweden, Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC). | $4.8M / Venture - Series Unknown / Feb 22, 2022 | |
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does EIR Ventures invest in?
EIR Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Funding Round stage. Most of the 13 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is EIR Ventures's check size?
EIR Ventures typically joins rounds of $20M–$73M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds EIR Ventures participates in.
How do I contact EIR Ventures?
Public channels for EIR Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at EIR Ventures?
The team at EIR Ventures includes Andreas Segerros (Founding Partner), Lene Gerlach (Partner) and Stephan Christgau (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
